PlainPharmaWatch

CMS Open Payments · Program Year 2024

Eton Pharmaceuticals, Inc.

Eton Pharmaceuticals, Inc. reported $80,619.46 across General Payments, Research, and Ownership to 264 physicians and teaching hospitals across 264 transactions.

See the rankings → How this is sourced
$80.6K Below-median payer
All-tracks total
264 Above-median volume
Transactions
264 Above-median reach
Recipients
−$17.6K
General Payments vs PY2023

Eton Pharmaceuticals, Inc. reported $80,619.46 across all CMS Open Payments tracks (General + Research + Ownership) to 264 physicians and teaching hospitals in Program Year 2024 - ranking #1239 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $80,619.46, averaging $305.38 per recipient.

How Eton Pharmaceuticals, Inc.'s $80.6K all-tracks total breaks down

Eton Pharmaceuticals, Inc.'s payment reach score

Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.

Overall reach score

F

15/100

Total payments

F

11/100

Transaction volume

F

12/100

Physician reach

F

12/100

Payment type diversity

F

23/100

Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.

Compiled from official public sources by the publisher.

CMS Sunshine Act warrant

Manufacturer eton-pharmaceuticals-inc Eton Pharmaceuticals, Inc.

$80.6K · #1239/1,925 · 0.0% industry · PY2024

  • TOT $80.6K
  • RANK #1239
  • SHARE 0.0%
  • TXN 264
  • RCP 264
  • CAT 2
  • GEN $80.6K
  • ΔGEN −$17.6K
  • TOP1 64.4%
  • PY 2024

Volume peers

Nearest volume peer: Nvision Biomedical Technologies, Inc. ($80.7K)

Elekta Limited$81.6KVisionAir Solutions, LLC$81.4KNvision Biomedical Technolog…$80.7KEton Pharmaceuticals, Inc. (…$80.6KLouisville URS Solutions, LLC$80.5K
All-tracks payment totals near Eton Pharmaceuticals, Inc. (CMS Open Payments PY2024)

Eton Pharmaceuticals, Inc. sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →

Release-over-release change

General Payments changed from PY2023 to PY2024

Eton Pharmaceuticals, Inc.'s CMS-reported General Payments decreased by $17.6K (−17.9%) from PY2023 to PY2024.

How this year-over-year comparison is scoped

The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.

CMS source labels for this exact identifier: PY2022: ETON PHARMACEUTICALS, INC.PY2023: ETON PHARMACEUTICALS, INC.PY2024: Eton Pharmaceuticals, Inc.. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.

Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.

General Payments: PY2023 vs PY2024

Annual CMS-reported totals for this company, not an all-category Open Payments total

PY2023$98.2KPY2024$80.6K
PY2023
$98,240.11
PY2024
$80,619.46

What the Data Shows for Eton Pharmaceuticals, Inc.

CMS Open Payments is not a single ledger: the all-tracks total shown above is General Payments plus Research Payments plus Ownership/Investment interests, each with its own disclosure rules. For Eton Pharmaceuticals, Inc., that total blends General Payments (day-to-day consulting, meals, travel and speaking fees, shown separately above) with Research and Ownership/Investment interest records, each governed by its own CMS reporting rules. Data for a given Program Year arrives roughly a year after the period it covers; our methodology page documents the release cadence and how we standardize the tracks for cross-company comparison.

Of the 2 general-payment categories charted below, "Consulting Fee" is the largest at $74.1K across 53 transactions, 91.9% of this company's General Payments (see our methodology for how research and ownership payments are reported separately).

General Payment Breakdown by Type

Eton Pharmaceuticals, Inc. made 2 types of general payments. "Consulting Fee" is the largest category at $74.1K, 91.9% of General Payments.

How Eton Pharmaceuticals, Inc. divides its payments

General-payment categories, ordered by reported total

1. Consulting Fee$74.1K2. Food and Beverage$6.6K
Payment Type Amount Transactions
Consulting Fee $74.1K 53
Food and Beverage $6.6K 211

Recipient Concentration in General Payments

The five largest recipient relationships account for $73,519.61 (91.2%) of $80,619.46 in this company's General Payments records across 137 recipients.

General Payments scope note

Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.

Largest General-Payment relationships for Eton Pharmaceuticals, Inc.

The five named recipients with the highest reported General Payments from this company

Kanika Ghai$51.9KMitchell Geffner$10.1KQuentin Van Meter$6.0KMabel Yau$4.7KBradley Miller$795.16
  1. 1

    Kanika Ghai

    $51,886.50 across 13 reported transactions

  2. 2

    Mitchell Geffner

    $10,091.40 across 19 reported transactions

  3. 3

    Quentin Van Meter

    $6,000.00 across 6 reported transactions

  4. 4

    Mabel Yau

    $4,746.55 across 8 reported transactions

  5. 5

    Bradley Miller

    $795.16 across 4 reported transactions

Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.

Spend vs. Concentration

Eton Pharmaceuticals, Inc. ranks #1239 of 1,925 by total payments (bottom 36% by spend) but is notably more concentrated than that alone would suggest -- #420 of 1,838 by HHI (top 23% most concentrated). Its payments land on an unusually narrow set of recipients for its spend size.

00.00.00.00.14303.34351.44399.54447.64495.8Total payments ($M)Concentration (HHI, 0-10,000)
Eton Pharmaceuticals, Inc. (highlighted) among its 12 nearest HHI-concentration neighbors, Program Year 2024. Dashed lines mark this neighborhood's median payment total and median HHI. Hover a point for the company name. Source: company_concentration (CMS Open Payments general-payment recipients).
View all 12 companies in this HHI neighborhood as a list

Similarly Concentrated Companies

Companies whose General Payments are spread across recipients about as (un)evenly as Eton Pharmaceuticals, Inc.'s, measured by the same HHI concentration index above, not by payment size.

What HHI 2,500 means here

2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Eton Pharmaceuticals, Inc..

Circinus Medical Technology LLC

HHI 4376

Meticuly Inc.

HHI 4429

Kinamed, Inc.

HHI 4353

Spectra Medical Devices, LLC

HHI 4434

Companies with Similar Payment Volumes

Open a profile or compare a similar company's CMS-reported payment pattern with Eton Pharmaceuticals, Inc..

Showing 6 of 1,924 companies with CMS-reported payment data.

Put this to use

Eton Pharmaceuticals, Inc. ranks #1239 of 1,925 by all-tracks total payments, led by "Consulting Fee".

Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.

Data Source: Centers for Medicare & Medicaid Services (CMS) Open Payments, Program Year 2024. Data includes general payments, research payments, and physician ownership/investment interests as required by the Physician Payments Sunshine Act. Total industry payments: $13.9B across 1,925 companies.

Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer

This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

View saved (companies)
Download Eton Pharmaceuticals, Inc.'s data (CSV)
Embed this widget

Copy this snippet to embed a live-linked card on your own site.

Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.